[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532843":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":18,"responsibleParty":35,"collaborators":37,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":7,"maxAge":7,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":7,"overallStatus":59,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"The Royal Wolverhampton Hospitals NHS Trust","OTHER_GOV",null,[9],{"name":10,"affiliation":11,"role":12},"Viktoria Eleftheriadou","The Royal Wolverhampton NHS Trust","PRINCIPAL_INVESTIGATOR",[14],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","01902307999","viktoria.eleftheriadou@nhs.net",[19],{"facility":11,"status":7,"city":20,"state":7,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Wolverhampton","WV10 0QP","United Kingdom","UK",{"type":25,"coordinates":26},"Point",[27,28],-2.12296,52.58547,{"lat":28,"lon":27},[31,32],{"name":10,"role":15,"phone":7,"phoneExt":7,"email":17},{"name":33,"role":15,"phone":7,"phoneExt":7,"email":34},"Lorraine Jacques","lorraine.jacques@nhs.net",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[38],{"name":39,"class":40},"Incyte Biosciences International Sàrl","INDUSTRY","100532843","vitiligo-registry-for-adults-and-children-in-the-uk-100532843",false,"NCT06218082","Vitiligo Registry for Adults and Children in the UK","Vitiligo Registry for Adults and Children in the UK (VIRTUAL-UK)","VIRTUAL-UK","Inclusion Criteria:\n\n1. Paediatric and adult patients with vitiligo under management in secondary care.\n2. Written informed consent for study participation obtained from the patient or parents \u002F legal guardian, with assent as appropriate by the patient, depending on the level of understanding.\n3. Participants consent to participate in long-term follow up and access to all relevant medical records as needed by the study team\n4. Clinical diagnosis of vitiligo made by a dermatologist\n5. Willingness to comply with all study requirements.\n6. Competent use of English language, according to patient's age (capable of understanding patient questionnaires).\n\nExclusion Criteria:\n\n1. Insufficient understanding of the study by the patient and\u002For parent\u002Fguardian.\n2. Patients with vitiligo\u002Ftheir parents or guardians, who do not provide consent for participation.","ALL",{"count":51,"type":52},30,"ESTIMATED","1 Year","OBSERVATIONAL","Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo before the age of 30 years old.1 Vitiligo often presents in childhood and tends to be a lifelong disease, requiring prolonged courses of phototherapy.\n\nCurrently no national or international registry for patients with vitiligo exists. Individual dermatologists maintain a database of such patients, however no coordinated efforts have been made to combine these individual registries into a broader national registry. Finally, recently published British Association of Dermatologists (BAD) guideline for the management of vitiligo, recommended the development of a national registry for people with vitiligo undergoing systemic or light therapy to identify outcomes and safety.",[57,58],"Dermatologic Disease","Vitiligo","NOT_YET_RECRUITING","2026-04-08",{"date":62,"type":63},"2026-04-09","ACTUAL",{"date":65,"type":52},"2026-05-15",{"date":67,"type":52},"2030-02",{"name":5,"class":6},1]